JP Morgan Chase’s Calithera Biosciences, Inc CALA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-24,345
| Closed | -$79K | – | 7554 |
|
|
2022
Q4 | $79K | Buy |
24,345
+4,260
| +21% | +$10.2K | ﹤0.01% | 5444 |
|
|
2022
Q3 | $59K | Buy |
20,085
+14,264
| +245% | +$48.8K | ﹤0.01% | 5494 |
|
|
2022
Q2 | $14K | Sell |
5,821
-21,575
| -79% | -$100K | ﹤0.01% | 5979 |
|
|
2022
Q1 | $221K | Hold |
27,396
| – | – | ﹤0.01% | 5139 |
|
|
2021
Q4 | $364K | Buy |
27,396
+8,420
| +44% | +$212K | ﹤0.01% | 5021 |
|
|
2021
Q3 | $828K | Buy |
18,976
+11,873
| +167% | +$512K | ﹤0.01% | 4440 |
|
|
2021
Q2 | $297K | Buy |
7,103
+1,856
| +35% | +$81.6K | ﹤0.01% | 5025 |
|
|
2021
Q1 | $254K | Buy |
5,247
+838
| +19% | +$48.8K | ﹤0.01% | 5053 |
|
|
2020
Q4 | $433K | Buy |
4,409
+3,183
| +260% | +$279K | ﹤0.01% | 4453 |
|
|
2020
Q3 | $84K | Buy |
1,226
+120
| +11% | +$10.5K | ﹤0.01% | 4775 |
|
|
2020
Q2 | $117K | Buy |
1,106
+332
| +43% | +$39.4K | ﹤0.01% | 4502 |
|
|
2020
Q1 | $69K | Sell |
774
-27
| -3% | -$3.22K | ﹤0.01% | 4632 |
|
|
2019
Q4 | $91K | Sell |
801
-10,573
| -93% | -$795K | ﹤0.01% | 4937 |
|
|
2019
Q3 | $703K | Buy |
11,374
+10,901
| +2,305% | +$873K | ﹤0.01% | 4025 |
|
|
2019
Q2 | $36K | Sell |
473
-98
| -17% | -$11.1K | ﹤0.01% | 5303 |
|
|
2019
Q1 | $77K | Buy |
571
+174
| +44% | +$18.3K | ﹤0.01% | 4974 |
|
|
2018
Q4 | $32K | Sell |
397
-10,892
| -96% | -$1.07M | ﹤0.01% | 5224 |
|
|
2018
Q3 | $1.19M | Buy |
11,289
+5,172
| +85% | +$492K | ﹤0.01% | 3807 |
|
|
2018
Q2 | $612K | Buy |
6,117
+5,809
| +1,886% | +$658K | ﹤0.01% | 4085 |
|
|
2018
Q1 | $39K | Sell |
308
-22
| -7% | -$3.43K | ﹤0.01% | 4898 |
|
|
2017
Q4 | $55K | Buy |
+330
| New | +$84.5K | ﹤0.01% | 4865 |
|
|
2017
Q3 | – | Sell |
-87
| Closed | -$26K | – | 5275 |
|
|
2017
Q2 | $26K | Buy |
+87
| New | +$23.3K | ﹤0.01% | 4491 |
|
|
2016
Q4 | – | Sell |
-354
| Closed | -$23K | – | 5195 |
|
|
2016
Q3 | $23K | Buy |
354
+301
| +568% | +$19.4K | ﹤0.01% | 4178 |
|
|
2016
Q2 | $4K | Sell |
53
-13,325
| -100% | -$1.33M | ﹤0.01% | 4506 |
|
|
2016
Q1 | $1.52M | Sell |
13,378
-347
| -3% | -$39.3K | ﹤0.01% | 2846 |
|
|
2015
Q4 | $2.1M | Buy |
+13,725
| New | +$2.06M | ﹤0.01% | 2730 |
|
|
2015
Q2 | – | Sell |
-6,374
| Closed | -$2.09M | – | 4249 |
|
|
2015
Q1 | $2.09M | Sell |
6,374
-212
| -3% | -$75.4K | ﹤0.01% | 2844 |
|
|
2014
Q4 | $2.66M | Buy |
+6,586
| New | +$1.72M | ﹤0.01% | 2790 |
|
Other funds holding CALA
JP Morgan Chase's CALA Position: Q1 2023 in Review
JP Morgan Chase sold out of Calithera Biosciences, Inc (CALA) in Q1 2023, closing a stake of 24,345 shares — an estimated $79K sold.
JP Morgan Chase first reported a position in CALA in Q4 2014 and held it in 28 quarters. The position peaked at $2.66M in Q4 2014. 2 funds tracked by Wall St. Rank hold CALA as of Q1 2023.
- JP Morgan Chase reported no remaining Calithera Biosciences, Inc position as of Q1 2023 after selling out during the quarter.
- JP Morgan Chase sold 24,345 Calithera Biosciences, Inc shares in Q1 2023, an estimated $79K.
- JP Morgan Chase first reported a position in Calithera Biosciences, Inc in Q4 2014 and held it in 28 quarters.
- JP Morgan Chase's Calithera Biosciences, Inc position peaked at $2.66M in Q4 2014.
- 2 funds tracked by Wall St. Rank held Calithera Biosciences, Inc as of Q1 2023.
Based on JP Morgan Chase's 13F filing for Q1 2023, filed 11 May 2023.